Early screening and prevention of preterm preeclampsia with aspirin: time for clinical implementation.


  • Date de publication : 2017-09-09

Référence

Rolnik DL, O'Gorman N, Roberge S, Bujold E, Hyett J, Uzan S, Beaufils M, da Silva Costa F. Early screening and prevention of preterm preeclampsia with aspirin: time for clinical implementation. Ultrasound Obstet Gynecol. 2017;:. doi: 10.1002/uog.18899. PubMed PMID: 28887883.

Information Complémentaire

Lien vers PubMed

Résumé

Despite all the research published in the last three decades on screening and prevention of preeclampsia (PE), this condition remains one of the main causes of maternal and perinatal morbidity and mortality, both in low and high-income countries. It affects 2-8% of all pregnancies, being responsible for one out of five maternal deaths and 15% of all premature deliveries(1) . An ideal screening test requires identification of women at high-risk of developing severe and early-onset forms of the disease, a high detection rate (DR) with an acceptable false-positive rate (FPR), and the availability of an effective preventive measure(2) .